BACKGROUND: The aim of this study is to evaluate the clinical characteristics and outcomes in 2019 novel coronavirus patients and to help clinicians perform correct treatment and evaluate prognosis and guide the treatment. METHODS: 239 patients who were diagnosed with COVID-19 were included in this study. Patients were divided into the improvement group and the death group according to their outcome (improvement or death).Clinical characteristics and laboratory parameters were collected from medical records. Continuous variables were tested by independent sample T test, and categorical variables were analyzed by chi-square test or Fisher exact test. Cox proportional hazard regression model was used for survival analysis in death patients. The time-dependent AUC curves based on white blood cell count, lymphocyte count, white blood cell, lymphocyte count, neutrophil counts age, blood urea nitrogen and C-reactive protein were plotted. RESULTS: Efficacy evaluation indicated that 99 patients (41.4%) had deteriorated, and 140 patients (58.6%) had improved. Oxygen saturation, hemoglobin levels, infection-related indicators, lymphocyte and platelets counts, C-reactive protein, serum albumin, liver and kidney function and lactate dehydrogenase in improvement group were statistically significant between the improvement and death groups. Survival analysis revealed that comorbidities, lymphocyte counts, platelet count, serum albumin, C-reactive protein level and renal dysfunction may be risk factors in patients with COVID-19. CONCLUSION: Patients with comorbidities, lower lymphocyte counts in hemogram, platelet count and serum albumin, high C-reactive protein level and renal dysfunctionmay have higher risk to death. More attention should be givento risk management in the progression of COVID-19.

Background: Previous studies have shown that the dysregulation of lncRNAs participates in non-small cell lung cancer (NSCLC) development. The purpose of this study was to research the biological function of lncRNA SNHG14 and its molecular mechanism in NSCLC progression. Methods: RT-PCR was applied for investigating the expression of SNHG14, miR-206 and G6PD. The progression of NSCLC was detected by CCK-8, Transwell and western blot assays. The targets of SNHG14 and miR-206 were measured by dual-luciferase reporter assay. Results: We found a higher expression of SNHG14 in NSCLC and upregulation of SNHG14 contributed to NSCLC cell proliferation, invasion and migration. However, knockdown of SNHG14 showed the opposite effect on the progression of NSCLC. Specifically, SNHG14 negatively regulated miR-206 expression by binding with it directly. Furthermore, G6PD served as the target of miR-206. Rescue experiments showed that SNHG14 promoted G6PD expression by inhibiting miR-206. Conclusions: LncRNA SNHG14 contributed to NSCLC progression through miR-206/G6PD axis, providing novel clues for understanding the mechanism of NSCLC.

No abstract